Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory submission

Surrozen submits IND for SZN-8141

Analysis based on 7 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026

Sentiment
10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The IND submission is a positive regulatory milestone for Surrozen, potentially advancing its lead candidate toward clinical trials and validating its Wnt-based platform. However, the stock traded down 1.98% to $22.31, reflecting modest market reaction and the early-stage nature of the development.

Biotechnology Pharmaceuticals

Surrozen, Inc. announced the submission of an Investigational New Drug (IND) application to the U.S. United States — Food and Drug Administration for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody, for the treatment of diabetic macular edema (DME). The company plans to evaluate SZN-8141 in the DUET Phase 1b/2a clinical trial, expected to initiate by year-end 2026 with initial data anticipated in the second half of 2027. Preclinical studies showed SZN-8141 reduced neovascularization and vascular leakage more effectively than monotherapies. Surrozen aims to differentiate SZN-8141 from existing anti-VEGF therapies by combining Wnt pathway activation with VEGF inhibition.

stock
Surrozen is the developer of SZN-8141 and the submitter of the IND. This milestone advances its lead candidate toward clinical trials, potentially enhancing its pipeline value, though the stock saw a slight decline.
Importance 100.0 Sentiment 10.0
govactor
The FDA is the regulatory authority reviewing the IND application. Its approval is required for Surrozen to proceed with clinical trials, making it a key gatekeeper in this event.
Importance 80.0 Sentiment 0.0
per
Craig Parker, CEO of Surrozen, is the public spokesperson for the announcement. His leadership is central to the company's strategic direction, though the event does not directly affect him personally.
Importance 30.0 Sentiment 0.0
stock
Merck is mentioned as having a competing Wnt agonist, MK-3000, which has shown proof of concept in DME. This provides competitive context but does not directly impact Merck's operations.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.